報價延遲最少15分鐘:2026/04/25 17:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.22 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.42/-2.56
|
|
企業價值
103.21M
|
| 資產負債 |
|
每股賬面淨值
2.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
53.74M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD). |
